Finally, the clinical benefits of SGLT2 inhibitors in HF go beyond glycemic control, as demonstrated by the DAPA-HF study; initiating a new era in the treatment of patients with HF with reduced ejection fraction. The gene discussed is SLC5A2; the disease is hydrops fetalis.